Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor ...

A bitter and bloody war in Ukraine has devastated the country, further isolated Russia from the West and fueled economic insecurity around the world. Officials said more than 30 drones had been ...

Republican’s remarks raise fears there could be repeat of 2021 violence despite initially saying he would accept a ‘fair’ result ...

The 27-member bloc’s foreign policy chief visited Kyiv and said EU support is necessary to fight Russian aggression. US eases restrictions for a few contractors to work away from the front lines ...